
FAMILY HISTORY AS AN IMPORTANT FACTOR
FOR STRATIFYING PARTICIPANTS IN GENETIC
STUDIES OF MAJOR DEPRESSION Zalar B, Blatnik A, Maver A, Klemenc-Ketiš Z, Peterlin B *Corresponding Author: Professor Borut Peterlin, Clinical Institute of Medical Genetics, Division of Obstetrics and Gynecology,
University Medical Center Ljubljana, Šlajmerjeva 3, 1000 Ljubljana, Slovenia. Tel: +386-1-5401-137. E-mail:
borut.peterlin@guest.arnes.si page: 5
|
INTRODUCTION
Depression is a major cause of disease and disability.
It consists of several symptoms, such as depressed mood,
loss of interest or pleasure, decreased energy, feelings of
guilt or low self-worth, disturbed sleep or appetite, and
poor concentration. One-third of all people seeking psychiatric
help are depressed; in more economically developed
countries, one in five people will be depressed at least once
in his/her life, and in poorer ones, this ratio is much worse.
Major depression usually strikes without a a discernible
triggering event. This can be confusing and frustrating
for both the person affected and his/her surroundings.
People expect their illnesses to have clear causes, but many
serious diseases, such as cancer, usually have none. Major
depression is indeed a serious disease that often causes
despair and hopelessness so profound that the person loses
all interest in life, becomes incapable of feeling pleasure,
and may be unable to get out of bed or eat for days at a
time. The total annual cost of depression in Europe is about
253 Euro per inhabitant [1].
Genetic susceptibility to major depressive disorder
(MDD) is a field of study that has baffled many researchers;
while it has shown great promise, it has actually yielded
very few tangible results. Major depressive disorder has
long been known to be moderately heritable. Twin studies
have repeatedly shown the heritability of major depression
to be about 37.0-38.0% [2,3]. Different approaches to studying the genetics of MDD have so far been consistent
only in their inconsistency; linkage studies, candidate gene
approaches, studies of gene-environment interaction, and
more recent genome-wide association studies (GWAS)
have failed to give significant or reproducible results [4,5].
Genome-wide association studies in particular have shattered
hopes of finding significant common risk variants.
Previously detected associations with genes such as those in
the monoamine synthesis pathway have not been replicated
in GWAS and no new, clear-cut candidates significantly
associated with MDD have been discovered [6,7]. These
results are in stark contrast to results for other complex
diseases such as diabetes, Crohn’s disease, and rheumatoid
arthritis, where GWAS have been considerably more successful
in identifying potentially interesting loci [8-10].
Researchers are now trying to find novel approaches in their
quest for the missing heritability of MDD [11].
Many reviewers agree that the aforementioned failure
of GWAS could be due to the fact they were underpowered
[12]. A great number of different loci might play a role in
determining a person’s predisposition to develop MDD, but
if that is indeed the case, the effect of each contributing variant
could be exceedingly small. It has been estimated that
sample sizes in excess of 50,000 might be needed for variants
with genome-wide significance to be discovered [11].
A possible approach that might enable researchers
to lower the necessary number of participants in future
studies would be to concentrate on the various subtypes
of depressive disorders, as there is evidence MDD is a genetically
heterogeneous disorder [13]. Depression is more
heritable in women and is associated with different genetic
variants in both sexes [14,15]. Studying patients with early
onset disease, choosing patients with more severe forms of
the disease and a higher recurrence rate, as well as focusing
on various clinical subtypes, could also help distinguish
between different genetic influences. It is also important to
acknowledge that there is a considerable overlap between
MDD and other psychiatric disorders such as bipolar disorder
and generalized anxiety disorder (GAD). Some studies
show that the genetic factors underlying both MDD and
GAD are essentially the same [16-19].
Another approach to subdividing patients with MDD
that has occasionally been used in the past, is to enquire about
their family history of depression. A positive family history
is the most important risk factor for developing a depressive
disorder and is often found in patients with more severe and
recurrent disease and an earlier age of onset [20,21]. Linkage
studies performed in families with several affected members
have shown that many different loci could be associated with
the familial form of the disease [22,23]. Estimates of single
nucleotide polymorphism (SNP) heritability performed so
far seem to indicate that more than 50.0% of MDD heritability
is due to common variants [24], but the possibility that
rare variants of great effect also account for some MDD
heritability cannot be excluded. It is therefore possible that
both combinations of common risk variants and specific rare
variants are at play in familial cases.
Based on these findings, our study aimed to explore
the connection between the family history of depression
and the presence of common genetic risk factors for MDD.
First, we set out to determine the allele and genotype distributions
for the extensively studied SLC6A4, COMT
and PCLO polymorphisms in Slovene patients with MDD
and to compare them to healthy controls. We then tried
to detect any differences in the prevalence of these putative
genetic risk variants in MDD patients with a positive
family history of depressive disorder compared to sporadic
cases with no affected relatives.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|